JOHNSON BRENT 4
4 · IRADIMED CORP · Filed Apr 2, 2020
Insider Transaction Report
Form 4
IRADIMED CORPIRMD
JOHNSON BRENT
Exec. VP, Sales & Marketing
Transactions
- Sale
Common Stock
2020-03-31$20.00/sh−4,000$80,000→ 2,940 total - Sale
Common Stock
2020-04-01$20.16/sh−4,000$80,640→ 2,940 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-03-31−4,000→ 135,685 totalExercise: $1.48Exp: 2023-12-31→ Common Stock (4,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-04-01−4,000→ 131,685 totalExercise: $1.48Exp: 2023-12-31→ Common Stock (4,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-04-02−1,211→ 130,474 totalExercise: $1.48Exp: 2023-12-31→ Common Stock (1,211 underlying) - Exercise/Conversion
Common Stock
2020-03-31$1.48/sh+4,000$5,920→ 6,940 total - Exercise/Conversion
Common Stock
2020-04-02$1.48/sh+1,211$1,792→ 4,151 total - Sale
Common Stock
2020-04-02$20.17/sh−1,211$24,426→ 2,940 total - Exercise/Conversion
Common Stock
2020-04-01$1.48/sh+4,000$5,920→ 6,940 total
Footnotes (5)
- [F1]The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.
- [F2]This transaction was executed in multiple trades at prices ranging from $20.00 to $20.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $20.15 to $20.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $20.00 to $20.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This option, representing a right to purchase a total of 199,759 shares, was granted on December 31, 2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. 49,939 shares from this award were previously exercised in December 2015.